drugset / Trial / NCT01498081

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

NCT01498081

Phase 2 Completed 39 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

This study in COPD patients will investigate the bronchodilatory effect of AZD2115. AZD2115 will be tested versus placebo and active comparators. The safety and tolerability of AZD2115 including investigations of clinically relevant systemically mediated effects will also be investigated.

Timeline

Start
2012-03
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2115 Unknown 25 ug Inhaled
Subject AZD2115 Unknown 80 ug Inhaled
Subject AZD2115 Unknown 240 ug Inhaled
Comparator Indacaterol Other / unclassified 150 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled